1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Marksans Pharma Limited

Marksans Pharma Limited

MARKSANS.NS
Marksans Pharma LimitedIN flagNational Stock Exchange of India
242.37
INR
+1.18
- -
109.83BMarket Cap

Total Valuation

Marksans Pharma Limited carries a market capitalization of 109.83B, placing it among publicly traded companies globally. Its enterprise value stands at 64.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap109.83B
Enterprise Value64.80B

Share Statistics

Marksans Pharma Limited currently has 453.16M shares outstanding.

Shares Outstanding453.16M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Marksans Pharma Limited trades at a trailing price-to-earnings ratio of 16.99. The price-to-sales ratio is 2.41, and the price-to-book ratio stands at 156.72.

PE Ratio16.99
PS Ratio2.41
PB Ratio156.72
P/TBV Ratio2.46
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Marksans Pharma Limited trades at an EV/EBITDA multiple of 12.90 and an EV/FCF ratio of 358.44. The EV/Sales ratio of 2.20 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 12.90 provides insight into valuation relative to core operating earnings.

EV / Sales2.20
EV / EBITDA12.90
EV / EBIT12.90
EV / FCF358.44

Financial Position

Marksans Pharma Limited maintains a current ratio of 5.17, meaning it holds 5.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.25, indicating elevated leverage, while an interest coverage ratio of 20.81 demonstrates strong ability to service its debt obligations.

Current Ratio5.17
Quick Ratio1.89
Debt / Equity11.25
Debt / EBITDA0.68
Interest Coverage20.81

Financial Efficiency

Marksans Pharma Limited posts a return on equity of 55.25 and a return on invested capital of 11.94.

Return on Equity (ROE)55.25
Return on Assets (ROA)11.77
Return on Invested Capital (ROIC)11.94
Return on Capital Employed (ROCE)38.91
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.41

Taxes

Over the trailing twelve months, Marksans Pharma Limited has paid 1.40B in income taxes, reflecting an effective tax rate of 25.06.

Income Tax1.40B
Effective Tax Rate25.06

Stock Price Statistics

Marksans Pharma Limited's stock has declined approximately -7.26229% over the past 52 weeks. The 50-day moving average sits at 193.62, while the 200-day moving average is 181.56.

Beta (5Y)N/A
52-Week Price Change-7.26229%
50-Day Moving Average193.62
200-Day Moving Average181.56
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Marksans Pharma Limited generated 29.51B in revenue and converted that into 4.18B in net income, yielding earnings per share of 9.28. EBITDA reached 5.02B, while operating income came in at 5.02B.

Revenue29.51B
Gross Profit16.74B
Operating Income5.02B
Pretax Income5.61B
Net Income4.18B
EBITDA5.02B
EBIT5.02B
Earnings Per Share (EPS)9.28

Balance Sheet

Marksans Pharma Limited holds 9.95B in cash and equivalents against 3.43B in total debt, resulting in a net debt position of -6.05B. Total book value stands at 453.16M, with working capital of 21.96B providing operational flexibility.

Cash & Cash Equivalents9.95B
Total Debt3.43B
Net Debt-6.05B
Equity (Book Value)453.16M
Book Value Per Share1.00
Working Capital21.96B

Margins

Marksans Pharma Limited operates with a gross margin of 56.72, reflecting its pricing power and cost economics. The operating margin of 17.02 and net profit margin of 14.16 provide insight into operational efficiency.

Gross Margin56.72
Operating Margin17.02
Pretax Margin19.00
Profit Margin14.16
EBITDA Margin17.02

Stock Splits

Marksans Pharma Limited's most recent stock split took place on March 11, 2008 with a 1:10 split ratio.

Last Split Date3/11/2008
Split Ratio1:10

Scores

Marksans Pharma Limited posts an Altman Z-Score of 7.23, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score7.23